Loading clinical trials...

Curcumin in Rheumatoid Arthritis | Clinical Trials | Clareo Health

COMPLETEDEARLY_PHASE1

Curcumin in Rheumatoid Arthritis

Curcumin in Rheumatoid Arthritis - ACross-Over Pilot Study

NCT00752154•University of California, Los Angeles

Summary

Curcuma longa or turmeric is a tropical plant native to south and southeast tropical Asia. Perhaps the most active component in turmeric is curcumin which may make up 2-5% of the total spice in turmeric. The study drug being tested in this study is curcumin. This study is called a cross-over study because all subjects will receive the study drug for a certain amount of time and then switch to placebo (an inactive substance) for a certain time or vice versa. The subject's participation may last up to 8 months. The subject will be randomized (by chance; like flipping a coin) to receive either the study drug, curcumin, or placebo for 4 months. After 4 months, if the subject was taking curcumin they will stop taking it and begin to take placebo and if the subject was taking placebo they will stop taking it and begin taking curcumin for the remaining 4 months. By completion of the study, all 40 subjects will have taken curcumin and placebo for 4 months each. Curcumin/placebo will be provided in capsule form and the subject will take it by mouth. The dose dose will be increased every week for up to a total of 4 grams per day. Subjects will have blood tests, complete questionnaires, and be seen by the study doctor.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age ≥ 18 years; read and understand English
•2. Stable dose of non-steroidal anti-inflammatory agents (NSAID) for ≥ 2 weeks.
•3. Oral prednisone or equivalent ≤ 10 mg daily and stable dose for ≥ 2 weeks(and must be kept stable throughout the duration of the protocol).
•* ESR \> 20 mm/hr, or CRP \> 0.8 mg/dl
•4. May be using any of the following DMARDs: methotrexate, sulfasalazine, hydroxychloroquine or leflunomide. If using any of these DMARDs must be using them for ≥ 12 weeks and stable dose for ≥ 4 weeks. If using other DMARD, or DMARD combinations, these additional or other DMARDs must be stopped for ≥ 4 weeks before baseline visit. May also participate if patient not on DMARD,
•5. Subjects must be diagnosed with rheumatoid arthritis based on the revised American College of Rheumatology criteria:Presence of \> swollen and \> 6 tender joint count (28 joint count), and either ESR \> 20 mm/hr or CRP \> 0.8 mg/dl

Exclusion Criteria

•1. Acute medical conditions deemed as inappropriate by the investigators (acute heart failure, uncontrolled diabetes mellitus, uncontrolled hypertension)
•2. AST/ALT \> 1.5 upper limit of normal (ULN)
•3. Serum creatinine \> 1.6 mg/dl
•4. Hemoglobin/Hematocrit \< 10.0 gram/dl/ 30.0
•5. Platelet count \< 100,000
•6. Current use of warfarin (as there is a drug interaction between curcumin and warfarin).
•7. Currently on biologic therapy (must have stopped etanercept for ≥ 4 weeks or adalimumab or infliximab for ≥ 8 weeks at time of Time 1 visit),
•8. Women who are pregnant,
•9. Subjects who are taking digoxin, warfarin and/or heparin,
•10. Subjects with a history of antiphospholipid syndrome and other thrombophilic states,
+3 more criteria

Locations (2)

Swamy Venuturpualli, M.D., 8737 Beverly Blvd., #203

Beverly Hills, California, United States

UCLA, 1000 Veteran Avenue, Rehab Building, 3rd Floor

Los Angeles, California, United States

Key Dates

Start Date

January 1, 2010

Primary Completion Date

December 1, 2010

Completion Date

January 1, 2011

Last Updated

September 29, 2023

Enrollment

ACTUAL participants

Conditions

Rheumatoid Arthritis

Interventions

Curcumin (Longvida™)

DRUG

Clinical Cohort Construction and Therapeutic Effect Evaluation of Integrated Traditional Chinese and Western Medicine in the Treatment of Rheumatoid Arthritis

NCT07484243

Rheumatoid Arthritis (RA)Rheumatoid Arthritis-Associated Interstitial Lung Disease+1 more

View study

RECRUITINGPHASE1

A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases

NCT06647069

Systemic Lupus Erythematosus (SLE)Rheumatoid Arthritis (RA)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 29, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Curcumin in Rheumatoid Arthritis

Inclusion Criteria

Exclusion Criteria

Clinical Cohort Construction and Therapeutic Effect Evaluation of Integrated Traditional Chinese and Western Medicine in the Treatment of Rheumatoid Arthritis

A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases

Targeted Remotely-delivered Anti-inflammatory Interventions With Exercise for Rheumatoid Arthritis

Plant-Based Diet for Patients With Rheumatoid Arthritis

A Phase II Trial of SHR-3045 Injection in Patients With Rheumatoid Arthritis

An Ascending Dose Study of PIT565 in Participants With Rheumatoid Arthritis